Levialfa 500 Tablet contains Levetiracetam 500 mg, an antiepileptic medication used primarily for the treatment of partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in adults and pediatric patients. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby stabilizing neuronal activity and reducing seizure frequency. Levialfa 500 is indicated as adjunctive therapy in epilepsy management and may be used as monotherapy in certain cases. The drug is well-absorbed orally with rapid onset of action and minimal hepatic metabolism, reducing the potential for drug-drug interactions. Common adverse effects include somnolence, dizziness, headache, and fatigue, though it is generally well-tolerated. Dose adjustments may be necessary in patients with renal impairment. Levialfa 500 should be administered under medical supervision, with gradual dose titration to minimize side effects. Patients should not discontinue therapy abruptly to avoid increased seizure risk. Regular monitoring and adherence to prescribed dosing schedules are essential for optimal therapeutic outcomes. Levialfa 500 offers a reliable and effective option for seizure control, improving quality of life in individuals with epilepsy.